Neuroscience

Alzheimer's disease, Diabetes, Diet, Longevity, Med Lifestyle, Medical News, Metabolic syndrome, Neurocognitive disorders, Neuroscience
Glucose and lipid levels in early adulthood found to be associated with Alzheimer’s disease

Researchers from Boston University School of Medicine found that low HDL, high LDL, and high glucose levels at midlife are all associated with an increased risk of Alzheimer’s disease later

Diet, Gastroenterology, Med Lifestyle, Medical News, Metabolic syndrome, Mood disorders, Neurocognitive disorders, Neuroscience
Gut metabolite found to affect brain function through reduction of glial cells

A Caltech research team has demonstrated how gut metabolite, 4-ethylphenyl sulfate (4EPS), induces anxiety-like behaviors in mice through the reduction of oligodendrocytes. For the last decade, many papers have been

Alzheimer's disease, Biotechnology, Genetics, Longevity, Med Lifestyle, Medical News, Neurocognitive disorders, Neuroscience, World health
Blood test that identifies risk of Alzheimer’s disease shown to be highly accurate in large study

Researchers from Washington University School of Medicine in St. Louis have developed a highly reliable blood test for identifying Alzheimer’s disease, which uses the biomarkers amyloid beta proteins Aβ42 and

Biotechnology, Med Lifestyle, Medical News, Neurocognitive disorders, Neuroscience, World health
Stimulation of specialized ganglion restores full motor function in mice with Parkinson’s Disease

A research group from the University of Copenhagen have identified a specific area of neurons that when stimulated, restores full movement function in mice presenting Parkinson’s Disease. (Credit: A mouse

Immunology, Med Lifestyle, Medical News, Neurodevelopmental disorders, Neuroscience
Epstein-Barr virus suggested as leading cause of multiple sclerosis

After a longitudinal analysis found that those who had been previously infected with the Epstein-Barr virus (EBV) had a 32-fold increased risk of developing multiple sclerosis (MS), researchers are now

Biotechnology, COVID-19, Medical News, Mood disorders, Neuroscience, Pharmaceuticals, World health
Antidepressant fluvoxamine shown to significantly reduce hospitalizations due to COVID-19

A new randomized-controlled trial has shown fluvoxamine, an antidepressant, significantly reduces hospitalizations due to COVID-19 (79 [11%] of 741 in the fluvoxamine group .vs. 119 [16%] of 756 in the